Liquidia Past Earnings Performance
Past criteria checks 0/6
Liquidia's earnings have been declining at an average annual rate of -13.2%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 27.5% per year.
Key information
-13.2%
Earnings growth rate
22.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 27.5% |
| Return on equity | -178.7% |
| Net Margin | -755.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Is Liquidia (NASDAQ:LQDA) A Risky Investment?
Jul 18
Broker Revenue Forecasts For Liquidia Corporation (NASDAQ:LQDA) Are Surging Higher
Jan 19Liquidia Corporation's (NASDAQ:LQDA) P/S Still Appears To Be Reasonable
Dec 20Is Liquidia (NASDAQ:LQDA) Using Debt In A Risky Way?
Aug 17Need To Know: Analysts Are Much More Bullish On Liquidia Corporation (NASDAQ:LQDA) Revenues
Mar 18Is Liquidia (NASDAQ:LQDA) Using Too Much Debt?
Feb 06Liquidia (NASDAQ:LQDA) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Oct 25Liquidia: United Manages A Temporary Win
Sep 12Liquidia tumbles 33% after judge denies stay request in United Therapeutics patent dispute
Aug 30Liquidia Q2 2022 Earnings Preview
Aug 10Liquidia Vs. MannKind: Treprostinil Is The Big 'IF'
Jun 29Revenue & Expenses Breakdown
How Liquidia makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 15 | -112 | 69 | 39 |
| 31 Mar 24 | 16 | -108 | 58 | 47 |
| 31 Dec 23 | 17 | -79 | 45 | 43 |
| 30 Sep 23 | 18 | -58 | 34 | 35 |
| 30 Jun 23 | 18 | -51 | 31 | 32 |
| 31 Mar 23 | 17 | -37 | 28 | 19 |
| 31 Dec 22 | 16 | -41 | 33 | 19 |
| 30 Sep 22 | 14 | -46 | 35 | 19 |
| 30 Jun 22 | 14 | -44 | 34 | 19 |
| 31 Mar 22 | 13 | -41 | 31 | 18 |
| 31 Dec 21 | 13 | -35 | 24 | 20 |
| 30 Sep 21 | 10 | -39 | 22 | 20 |
| 30 Jun 21 | 7 | -47 | 23 | 24 |
| 31 Mar 21 | 4 | -54 | 24 | 27 |
| 31 Dec 20 | 1 | -60 | 23 | 32 |
| 30 Sep 20 | 0 | -58 | 22 | 35 |
| 30 Jun 20 | 0 | -57 | 17 | 38 |
| 31 Mar 20 | 8 | -49 | 14 | 41 |
| 31 Dec 19 | 8 | -48 | 14 | 40 |
| 30 Sep 19 | 9 | -43 | 10 | 41 |
| 30 Jun 19 | 9 | -39 | 10 | 37 |
| 31 Mar 19 | 2 | -39 | 10 | 32 |
| 31 Dec 18 | 3 | -53 | 9 | 29 |
| 30 Sep 18 | 4 | -35 | 9 | 27 |
| 30 Jun 18 | 6 | -45 | 9 | 26 |
| 31 Mar 18 | 7 | -47 | 10 | 26 |
| 31 Dec 17 | 7 | -29 | 10 | 25 |
| 31 Dec 16 | 13 | -16 | 5 | 23 |
Quality Earnings: LQDA is currently unprofitable.
Growing Profit Margin: LQDA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LQDA is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.
Accelerating Growth: Unable to compare LQDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LQDA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (13%).
Return on Equity
High ROE: LQDA has a negative Return on Equity (-178.74%), as it is currently unprofitable.